Another study from the same group reported that inhibitor treatments for OC or the RANKL on the primary myeloma cells bearing SCID-hu reduced bone resorption and tumor burden, but such treatments to the mice with primary myeloma cells from the extramedullary disease patient did not affect this (Yaccoby et al., 2002). This evidence concerns the gene TNFSF11 and plasma cell myeloma.